Extra: Why Is 23andMe Going Under? (Update)

Episode Summary

Executive Summary: The episode revisits 23andMe’s promise and unraveling: a consumer DNA-testing pioneer that aimed to democratize genetic health information and research, but struggled with a flawed one-time purchase model, scientific limitations, privacy concerns, and regulatory and execution problems. A follow-up interview with WSJ reporter Rolf Winkler frames the company’s collapse in valuation and its uncertain future under potential private ownership.

Main Topics: 23andMe’s founding vision and consumer DNA testing boom (Priority: 5/5): Anne Wojcicki explains why she started 23andMe: to shift healthcare toward prevention, consumer choice, and data-driven self-knowledge rather than profit from illness. The company helped popularize direct-to-consumer genetics. FDA regulation and health-report validation (Priority: 5/5): The FDA forced 23andMe to halt health interpretations in 2013 and later approve specific risk reports, underscoring that the company’s health offerings were treated as medical claims requiring oversight. Privacy, ethics, and data-use concerns (Priority: 5/5): The discussion addresses law enforcement uses like the Golden State Killer case, concerns about misuse by governments or employers, and 23andMe’s insistence on consent-based sharing and privacy controls. Scientific limits and behavior-change skepticism (Priority: 4/5): Wojcicki argues genetic risk information can empower people, while the host cites research suggesting DNA reports rarely change behavior significantly and may mainly attract already motivated users. Genetic data as a research and drug-discovery asset (Priority: 4/5): 23andMe’s database became its most valuable long-term asset through partnerships with pharma companies like GSK and through internal research programs aimed at discovering therapeutics. Company collapse, SPAC overvaluation, and financial failure (Priority: 5/5): Rolf Winkler explains that despite popularity and big projections, 23andMe never found a durable profitable model; after a SPAC-fueled peak, its enterprise value fell to roughly zero. Family revelations and identity consequences (Priority: 3/5): The episode explores how DNA testing can reveal hidden family relationships, reshaping identity, redefining family, and exposing adoption or paternity secrets.

Key Arguments: 23andMe was built to empower individuals with access to their own genetic information and to make healthcare more preventive and consumer-centered. The company’s health reports required FDA approval because they effectively functioned as medical products, not just informational tools. Privacy is central to 23andMe’s model, and users should control how their data is shared; consent is framed as the meaning of privacy. Genetic risk results are useful only if people can act on them, but evidence for sustained lifestyle change from such reports is weak. 23andMe’s most durable value proposition became its research database and pharma partnerships, not the one-time consumer test. The consumer business model was structurally weak because most people buy the test once, limiting recurring revenue. The SPAC-era projections for subscriptions and profitability were overly optimistic and ultimately not met. The company’s decline reflects a mix of business-model problems, long drug-development timelines, regulatory shocks, and reputational damage from the hack.

Data Points: Year of original Freakonomics episode: 2019 - The bonus episode replays and updates a prior conversation about home DNA testing. 23andMe founding year: 2006 - Wojcicki co-founded 23andMe with Linda Avey and Paul Cusenza. Total customers: about 10 million - The transcript says 23andMe has about 10 million total customers. Customers buying health reports: about 5 million - These users purchased the health report option in addition to ancestry results. Customers taking DNA tests overall: more than 30 million - The transcript notes the broader home DNA testing market size across services. FDA warning letter: November 2013 - The FDA ordered 23andMe to stop returning health interpretations until approvals were secured. FDA-authorized reports: 10 ailments or conditions - In 2017 the FDA cleared 23andMe to provide risk reports for specific conditions. 23andMe valuation after SPAC: around $6 billion - The company’s public-market debut and merger narrative initially implied a very high valuation. Current valuation / enterprise value: zero - Rolf Winkler says the company’s enterprise value is effectively zero. GSK investment: $300 million - GlaxoSmithKline invested in 23andMe for access to genetic data for drug discovery. Non-European customers: roughly 20% - Wojcicki says about one-fifth of customers are non-European. Diabetes lifetime risk in U.S. adults: roughly 40% - A CDC estimate cited in the transcript. Study sample size: about 1,000 users - The Robert Green diet/exercise study surveyed 23andMe and another company’s customers. Reported behavior change: nearly one-third - Survey participants said they made diet/exercise changes directly motivated by testing results. Sustainable change at six months: over 40% - Wojcicki cites sustained interest in changing diet six months later, though the host notes limitations in the study. 23andMe publications: over 150 - Wojcicki says the company has produced more than 150 publications. Parkinson’s sample size: over 19,000 people - Participant count in the company’s research database. Alzheimer’s high-risk participants: over 1 million people - Wojcicki cites this as a large research cohort. Heart disease participants: 800,000 people - Another cohort in the 23andMe research database. Colorectal cancer participants: over 10,000 people - Research cohort size cited by Wojcicki. Depression participants: 750,000 people - Research cohort size cited by Wojcicki. 23andMe hack year: 2023 - The company was later hacked, affecting its reputation. Voting control: 49.99% - Wojcicki reportedly controls this share of votes through super-voting shares.

Pivotal Quotes: "Right now, the valuation is zero." — Rolf Winkler: He summarizes 23andMe’s current financial state after its collapse from a multibillion-dollar valuation. "We specifically thought about, like, how do we make sure that we're not set up for crime, you know, for, like, the FBI to come and use this." — Anne Wojcicki: She describes early concerns about preventing misuse of customer DNA data. "Privacy is key to the company." — Anne Wojcicki: Wojcicki emphasizes that user choice and consent are central to 23andMe’s data policy.

Implications: Consumer genetics proved powerful for identity and research, but not as a simple consumer subscription business. The episode suggests future success depends on trust, regulation, and turning data into real medical value rather than hype.